文献速递类风湿关节炎脊柱关节炎其他结缔组织病

非戈替尼对男性炎症性疾病患者精液参数和性激素的影响:2期随机双盲安慰剂对照MANTA和MANTA-RAy研究结果

Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
PubMed 文献 · Ann Rheum Dis · 2023-05-03

MANTA和MANTA-RAy两项2期随机双盲安慰剂对照研究评估口服JAK1偏好性抑制剂非戈替尼200mg每日一次共13周对活动性炎症性肠病或炎症性风湿病男性患者精液参数和性激素的影响,主要终点为第13周精子浓度较基线下降≥50%的参与者比例,非戈替尼组8/120(6.7%)vs 安慰剂组10/120(8.3%),差值-1.7%(95%CI -9.3%至5.8%),精液参数和性激素未见临床相关变化。

要点

  • 非戈替尼200mg每日一次共13周对活动性炎症性肠病或炎症性风湿病男性患者精液参数和性激素无显著影响。
  • 主要终点第13周精子浓度较基线下降≥50%的比例:非戈替尼组6.7% vs 安慰剂组8.3%,差值-1.7%(95%CI -9.3%至5.8%)。
  • 非戈替尼耐受性良好,未见新发安全性事件。

核心结论

  • 结果提示,每日一次非戈替尼200mg治疗13周对活动性炎症性肠病或炎症性风湿病男性患者的精液参数或性激素无显著影响。

研究设计与样本

  • MANTA(NCT03201445)和MANTA-RAy(NCT03926195)为2期随机双盲安慰剂对照研究,分别纳入21-65岁活动性炎症性肠病和风湿性疾病(类风湿关节炎、脊柱关节炎或银屑病关节炎)男性患者。
  • 入选者精液参数需符合WHO定义的正常范围,两项研究中参与者按1:1随机接受每日一次双盲非戈替尼200mg或安慰剂治疗13周,主要终点汇总分析。
  • 两项研究共筛查631例患者,248例随机分配至非戈替尼200mg或安慰剂组。

主要发现

  • 达到主要终点(第13周精子浓度较基线下降≥50%)的比例:非戈替尼组8/120(6.7%)vs 安慰剂组10/120(8.3%),差值-1.7%(95%CI -9.3%至5.8%)。
  • 第13周精液参数(精子浓度、总活力、正常形态、总计数和精液量)和性激素(促黄体生成素、促卵泡激素、抑制素B和总睾酮)较基线未见临床相关变化,两组间可逆性模式也无差异。
  • 非戈替尼耐受性良好,未见新发安全性事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The phase 2 MANTA and MANTA-RAy studies aimed to determine if the oral Janus kinase 1 preferential inhibitor filgotinib affects semen parameters and sex hormones in men with inflammatory diseases. METHODS: MANTA (NCT03201445) and MANTA-RAy (NCT03926195) included men (21-65 years) with active inflammatory bowel disease (IBD) and rheumatic diseases (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), respectively. Eligible participants had semen parameters in the normal range per the WHO definition. In each study, participants were randomised 1:1 to receive once-daily, double-blind filgotinib 200 mg or placebo for 13 weeks for pooled analysis of the primary endpoint (proportion of participants with a ≥50% decrease from baseline in sperm concentration at week 13). Participants who met the primary endpoint were monitored over an additional 52 weeks for 'reversibility'. Secondary endpoints included change from baseline to week 13 in: sperm concentration, total motility, normal morphology, total count and ejaculate volume. Sex hormones (luteinising hormone, follicle stimulating hormone, inhibin B and total testosterone) and reversibility were exploratory endpoints. RESULTS: Across both studies, 631 patients were screened, and 248 were randomised to filgotinib 200 mg or placebo. Baseline demographics and characteristics were similar within indications between treatment groups. Numerically similar proportions of filgotinib-treated versus placebo-treated patients met the primary endpoint (8/120 (6.7%) vs 10/120 (8.3%)), Δ-1.7% (95% CI -9.3% to 5.8%)). There were no clinically relevant changes from baseline to week 13 in semen parameters or sex hormones, or patterns of reversibility between treatment groups. Filgotinib was well tolerated, with no new safety events. CONCLUSIONS: Results suggest that once daily filgotinib 200 mg for 13 weeks has no measurable impact on semen parameters or sex hormones in men with active IBD or inflammatory rheumatic diseases.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Reinisch W, Hellstrom W, Dolhain RJEM, et al. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies. Ann Rheum Dis. 2023. PMID: 37137672. doi:10.1136/ard-2023-224017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。